Pluronic P123-docetaxel conjugate micelles: Synthesis characterization, and antitumor activity

Journal of Biomedical Nanotechnology

Volumn 9, Issue 12, 2013, Pages 2007-2016

  Liu, Zhihong ^a   Wang, Yutao ^a   Zhang, Juan ^a   Li, Min ^a   Liu, Yongjun ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Antitumor activity.; Conjugate; Docetaxel; Micelles; Pluronic P123

Indexed keywords

ANTI-TUMOR ACTIVITIES; CONJUGATE; CRITICAL MICELLE CONCENTRATION (CMC); DOCETAXEL; MEAN PARTICLE SIZE; PLURONIC P123; SELF-ASSEMBLY BEHAVIORS; SUCCINIC ANHYDRIDE;

CELL CULTURE; CRITICAL MICELLE CONCENTRATION; DRUG PRODUCTS; SOLUTIONS;

MICELLES;

DOCETAXEL; DUOPAFEI; PLURONIC P123; POLOXAMER; SUCCINIC ANHYDRIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; COVALENT BOND; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG ABSORPTION; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MICELLE; MOUSE; NONHUMAN; PH; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HEP G2 CELLS; HUMANS; MICE; MICELLES; NANOCONJUGATES; POLOXALENE; TAXOIDS;

EID: 84888810175     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1706     Document Type: Article

References (33)

1. J. E. Cortes and R. Pazdur, Docetaxel. J. Clin. Oncol. 13, 2643 (1988).
2. A. T. van Oosterom and D. Schrijvers, Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs 6, 356 (1995).
3. L. van Zuylen, J. Verweij, and A. Sparreboom, Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19, 125 (2001).
4. A. J. Ten Tije, J. Verweij, W. J. Loos, and A. Sparreboom, Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin. Pharmacokinet. 42, 665 (2003).
5. G. W. Qu, X. L. Wu, L. F. Yin, and C. Zhang, N -octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: Preparation, characterization, and pharmacokinetics. Biomed. Pharmacother. 66, 46 (2012).
6. Z. G. Yuan, D. W. Chen, S. T. Zhang, and Z. D. Zheng, Preparation, characterization and evaluation of docetaxel-loaded, folate-conjugated PEG-liposomes. Yakugaku Zasshi 130, 1353 (2010).
7. Y. M. Yin, F. D. Cui, C. F. Mu, M. K. Choi, J. S. Kim, S. J. Chung, C. K. Shim, and D. D. Kim, Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J. Controlled Release 140, 86 (2009).
8. V. Sanna, A. M. Roggio, A. M. Posadino, A. Cossu, S. Marceddu, A. Mariani, V. Alzari, S. Uzzau, G. Pintus, and M. Sechi, Novel docetaxel-loaded nanoparticles based on poly(lactide-cocaprolactone) and poly(lactide-co- glycolide-co-caprolactone) for prostate cancer treatment: Formulation, characterization, and cytotoxicity studies. Nanoscale Res. Lett. 6, 260 (2011).
9. M. J. Ernsting, W. D. Foltz, E. Undzys, T. Tagami, and S. D. Li, Tumor-targeted drug delivery using MR-contrasted docetaxel- carboxymethylcellulose nanoparticles. Biomaterials 33, 3931 (2012).
10. S. W. Lee, M. H. Yun, S. W. Jeong, C. H. In, J. Y. Kim, M. H. Seo, C. M. Pai, and S. O. Kim, Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J. Controlled Release 155, 262 (2011).
11. L. L. Wang, Z. H. Liu, D. H. Liu, C. X. Liu, Z. Juan, and N. Zhang, Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. Int. J. Pharm. 413, 194 (2011).
12. H. Ringsdorf, Structure and properties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 51, 135 (1975).
13. M. J. Vicent, L. Dieudonne, R. J. Carbajo, and A. Pineda-Lucena, Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin. Drug Deliv. 5, 593 (2008).
14. R. Tong and J. J. Cheng, Anticancer polymeric nanomedicines. Polym. Rev. 47, 345 (2007).
15. C. Li and S. Wallace, Polymer-drug conjugates: Recent development in clinical oncology. Adv. Drug Deliv. Rev. 60, 886 (2008).
16. Z. G. Xie, T. C. Lu, X. S. Chen, Y. H. Zheng, and X. B. Jing, Synthesis, self-assembly in water, and cytotoxicity of MPEG-block-PLLA/DX conjugates. J. Biomed. Mater. Res. Part A 88A, 238 (2009).
17. A. S. Mikhail and C. Allen, Poly(ethylene glycol)-b -poly(ε- caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: Synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 11, 1273 (2010).
18. F. Esmaeili, R. Dinarvand, M. H. Ghahremani, M. Amini, H. Rouhani, N. Sepehri, S. N. Ostad, and F. Atyabi, Docetaxel-albumin conjugates: Preparation, in vitro evaluation and biodistribution studies. J. Pharm. Sci. 98, 2718 (2009).
19. E. Lee, H. Kim, I. H. Lee, and S. Jon, In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J. Controlled Release 140, 79 (2009).
20. J. B. Liu, P. Zahedi, F. Q. Zeng, and C. Allen, Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J. Pharm. Sci. 97, 3274 (2008).
21. W. Zhang, Y. Shi, Y. Z. Chen, J. Ye, X. Y. Sha, and X. L. Fang, Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 32, 2894 (2011).
22. W. Zhang, Y. Shi, Y. Z. Chen, S. Y. Yu, J. G. Hao, J. Q. Luo, X. Y. Sha, and X. L. Fang, Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur. J. Pharm. Biopharm. 75, 341 (2010).
23. P. Alexandridis, J. F. Holzwarth, and T. A. Hatton, Micellization of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: Thermodynamics of copolymer association. Macromolecules 27, 2414 (1994).
24. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov, Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54, 759 (2002).
25. E. V. Batrakova and A. V. Kabanov, Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Controlled Release 130, 98 (2008).
26. S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, and M. Ranson, Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90, 2085 (2004).
27. J. W. Valle, A. Armstrong, C. Newman, V. Alakhov, G. Pietrzynski, J. Brewer, S. Campbell, P. Corrie, E. K. Rowinsky, and M. Ranson, A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 29, 1029 (2011).
28. Z. H. Liu, D. H. Liu, L. L. Wang, J. Zhang, and N. Zhang, Docetaxel-loaded Pluronic P123 polymeric micelles: in vitro and in vivo evaluation. Int. J. Mol. Sci. 12, 1684 (2011).
29. H. M. Deutsch, J. A. Glinski, M. Hernandez, R. D. Haugwitz, V. L. Narayanan, M. Suffness, and L. H. Zalkow, Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32, 788 (1989).
30. R. B. Greenwald, C. W. Gilbert, A. Pendri, C. D. Conover, J. Xia, and A. Martinez, Drug delivery systems: Water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs design and in vivo effectiveness. J. Med. Chem. 39, 424 (1996).
31. C. L. Zhao, M. A. Winnik, G. Riess, and M. D. Croucher, Fluorescence probe techniques used to study micelle formation in watersoluble block copolymers. Langmuir 6, 514 (1990).
32. J. Aguiar, P. Carpena, J. A. Molina-Bolivar, and C. C. Ruiz, On the determination of the critical micelle concentration by the pyrene 1:3 ratio method. J. Colloid Interface Sci. 258, 116 (2003).
33. L. B. Wu, J. Zhang, and W. Watanabe, Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 63, 456 (2011).